Virax Biolabs Files 6-K Report

Ticker: VRAX · Form: 6-K · Filed: Apr 14, 2026

Sentiment: neutral

Topics: foreign-issuer, disclosure, corporate-filing

TL;DR

Virax Biolabs dropped a 6-K filing on 4/14/26 - check it for updates.

AI Summary

Virax Biolabs Group Ltd filed a 6-K report on April 14, 2026, detailing its operations and business address at BIOCITY GLASGOW, BO'NESS ROAD, NEWHOUSE LANARKSHIRE, ML1 5UH. The filing includes various documents such as the 6-K report itself, an exhibit (EX-99.1), and graphic files, indicating ongoing corporate disclosures.

Why It Matters

This filing provides an update on Virax Biolabs Group Ltd's corporate activities and disclosures, which is important for investors and stakeholders to monitor the company's status.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) and does not contain specific financial results or significant corporate actions that would immediately impact risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a 6-K filing?

A 6-K filing is a report of foreign issuer required by SEC rules 13a-16 and 15d-16, used to provide information that the company makes or is required to make public in its home country.

When was this 6-K filing accepted by the SEC?

The filing was accepted on 2026-04-14 at 08:43:45.

What is the SIC code for Virax Biolabs Group Ltd?

The SIC code for Virax Biolabs Group Ltd is 2835, which pertains to In Vitro & In Vivo Diagnostic Substances.

What are the included documents in this filing?

The filing includes a 6-K report, an exhibit (EX-99.1), and two graphic files.

What is the business address of Virax Biolabs Group Ltd?

The business address is BIOCITY GLASGOW, BO'NESS ROAD, NEWHOUSE LANARKSHIRE, ML1 5UH.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 14, 2026 regarding Virax Biolabs Group Ltd (VRAX).

View full filing on EDGAR

View on Read The Filing